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Abstract 
Vicenin-2, a C-glycoside flavone that is present in many plant sources, exerts potent anti-
inflammatory effects in a number of cell and animal models of inflammation. Ten-eleven 
translocation (TET)-2 has recently gained considerable attention due to the role it plays in 
regulating the inflammasome. We studied the ability of Vicenin-2 (V-2) to regulate a range 
of lipopolysaccharide (LPS) stimulated inflammatory activities in PMA-differentiated 
THP-1 cells and human primary mononuclear cells.  We also investigated the action of V-2 
on the secretion of NLRP3 inflammasome regulated cytokines (IL-1β and IL-18) by 
ELISA, and determined if V-2 can regulate the expression of NLRP3, IL-10, IL-1Ra and 
TET-2. The effect of V-2 on NF-κB signalling was investigated by fluorescent microscopy 
and gene reporter assay. Additionally, the effect of V-2 on LPS-induced phosphorylation 
of IKB-α was also investigated by Western blot analysis. 
V-2 down-regulated LPS-induced secretion of proinflammatory cytokines (TNF-α and IL-
1β), in both THP-1 and primary mononuclear cells. V-2 also decreased the LPS-stimulated 
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secretion of IL-18 in THP-1 cells. V-2 significantly down-regulated TNF-α induced NF-κB 
reporter activity in HEK293T transfected cells and attenuated IKB-α phosphorylation in 
THP-1 cells. V-2 treatment also induced enhanced nuclear staining of the p50 subunit and 
reduced p65 subunit of NF-κB.  
V-2 treatment alone increased the expression of anti-inflammatory cytokine IL-10 
expression and the regulator of the inflammasome; IL-1Ra, in the presence of LPS. V-2 
significantly decreased LPS-induced NLRP3 expression while concomitantly increasing 
TET-2 expression. 
This study demonstrates that the anti-inflammatory actions of V-2 are associated not only 
with increased IL-10 and IL-1Ra expression but also with TET-2 expression. Further work 
is required to establish if the effects of V-2 can be definitively linked to TET-2 activity and 
that these actions are mirrored in a range of relevant cell types. 
1. Introduction 
Flavone-C-glycosides are a class of naturally-occurring compounds known to have diverse 
anti-inflammatory actions [1]. Vicenin-2, a C-glycoside that is present in many plant 
sources, has been shown to exert potent anti-inflammatory effects both in vitro [2] and in 
an experimental colitis model [3]. Macrophages are immune cells that are ubiquitously 
expressed across tissues and play an important role in the development and resolution of 
the inflammatory response. For instance, exposure to bacterial lipopolysaccharide (LPS) 
induces an inflammatory phenotype in macrophages that is  characterised by the expression 
of many proinflammatory cytokines including TNF-α and IL-1β [4]. The proinflammatory 
activities of macrophages is also associated with activation of NLR Family Pyrin Domain 
Containing 3 (NLRP3)-dependent inflammasome [5] and the  nuclear transcription factor, 
NF-κB [6]. During the resolution of inflammation, macrophages produce mediators such as 
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IL-10 and Interleukin-1 receptor antagonist (IL-Ra), that in turn, down-regulate 
inflammatory processes [7]. THP-1 is a human monocytic leukaemia derived cell line that 
is one of the most widely used cell models for investigating monocytic differentiation and 
subsequent biological functions of differentiated cells [8]. THP-1 cells differentiated with 
Phorbol-myristate-acetate (PMA) have been shown to possess functional characteristics of 
mature macrophages [9, 10]. TET (ten-eleven translocation)-2 is an epigenetic modifier 
that has recently gained considerable attention in the pathophysiology of atherosclerosis 
and cardiovascular disease [11, 12]. TET-2 also plays an important role in the 
inflammatory response of macrophages [13], and loss of this regulator results in the up-
regulation of many inflammatory mediators following LPS stimulation [14]. To date, the 
ability of natural products to modulate TET-2 in human macrophages has not been 
reported and this study determined if the anti-inflammatory actions of V-2 was associated 
with changes in expression of TET-2 in THP-1 cells. 
2. Materials and Methods 
2.1. Cell culture  
Ethical approval was obtained from the Cardiff School of Health Sciences Research Ethics 
Committee (reference: 7758). All compounds and chemicals were sourced commercially: 
V-2 and LPS (E.coli) were purchased from Sigma Aldrich (UK) and reconstituted in 
dimethyl sulfoxide (DMSO). TNF-α was obtained from Peprotech (UK).   THP-1 cells 
(ATCC, UK) were cultured in supplemented RPMI 1640 (Gibco, UK). To differentiate 
cells, THP-1 (6 x 105 cells/ml) were treated with 5ng/ml PMA (Sigma Aldrich, UK) for 48 
hours then rested in PMA-free media for a further 48 hours before experiments. HEK293T 
(ATCC, UK) cells were cultured in supplemented DMEM (Gibco, UK). Human peripheral 
blood mononuclear cells (PBMCs) were obtained from a pooled buffy coat sample of five 
healthy donors. PBMCs were isolated from buffy coat using LymphoprepTM (Stemcell 
4 
 
Technologies, UK) according to manufacturer’s instructions. PBMCs were cultured in 
supplemented RPMI-1640 and stimulated with PMA (5ng/ml) for 48 hours. The cells were 
further cultured in fresh medium for 48 hours before experiments. 
2.2. Cytokine Analysis 
The level of cytokines in cell-free supernatants was measured using Enzyme-linked 
immunosorbent assay (ELISA). All ELISA kits (TNF-α (Cat. #DY210); IL-1β (Cat. 
#DY401) and IL-18 (Cat. # DY318-05)) were obtained from R & D systems (Oxford, UK) 
and undertaken using protocols outlined by manufacturer. 
2.3. RNA extraction and quantitative RT-PCR   
RNA was isolated from cell monolayer using TRIzol® reagent (Life Technologies, UK) 
according to manufacturer’s guidelines. RNA was converted to cDNA using high capacity 
cDNA reverse transcription kit (Applied Biosystems, Warrington, UK). Gene expression 
was analysed using Applied Biosystems Fast 7500 Real-Time PCR System (Applied 
Biosystems, UK). The comparative CT method was used to calculate relative gene 
expression. The SYBR® Green methodology was employed to measure the expression of  
IL-10 and  IL-1Ra using the primer sequences published in [15]. TET-2 and NLRP3 gene 
expression was determined using Taqman methodology. Pre-designed probes for GAPDH 
(Hs99999905_m1), GUSB (Hs00939627_m1), TET-2 (Hs00325999_m1) and NLRP3 
(Hs00918082_m1) were obtained from Thermofisher (UK). CT values of target genes were 
normalized against the housekeeping genes; GAPDH and GUSB. Untreated samples were 
used as experimental controls.  
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2.4. NF-κB gene reporter assay  
HEK 293T cells were co-transfected with 50ng of NF-κB and 5ng of the Renilla luciferase 
reporter plasmid DNA (Pr6tk; Promega, UK) using Lipofectamine® for 24 hours before 
experiment. Cells were lysed 24 hours after stimulation and analysed using Dual-glo 
luciferase assay (Promega, UK), in line with manufacturer’s guidelines. 
2.5 Western Blotting 
To extract total proteins, the cell culture media was removed from wells and Radio-
Immunoprecipitation Assay (RIPA) Buffer was added to wells and placed on ice for 5 
minutes. The cell lysate was centrifuged at 14,000 x g for 15 minutes at 4˚C. Protein 
concentration was determined using the PierceTM BCA Protein Assay Kit (Thermofisher, 
UK). A total of 25μg total protein was separated on 10% Bis-Tris NuPAGE® gels 
(Invitrogen Ltd, UK) and transferred to a nitrocellulose membrane using the iBlot® dry 
blotting system (Invitrogen Ltd., UK). The membrane was blocked with 5% Marvel milk 
powder for 1 hour then incubated with the primary antibody overnight at the dilution of 
1:300. The membrane was washed and incubated with HRP-conjugated secondary 
antibody for 1 hour. Subsequently, the membrane was visualised with ECL HRP-substrate 
(AmershamTM, UK) and exposed to HyperfilmTM ECL film (Sigma Aldrich, UK). 
2.6 Immunofluorescence. 
THP-1 cells were seeded at a density of 6 x 105 cells/ml in a multi-well plate containing 
sterile 1.6mm coverslips (EMS, Hatfield, UK). Cells were differentiated with PMA as 
described in 2.1. Differentiated THP-1 cells were stimulated with V-2 for 1 hour before 
stimulation with LPS for 30 minutes. The cells were then fixed with 4% paraformaldehyde 
for 10 minutes then incubated with 0.25% Triton X-100 (Sigma, Aldrich, UK) for a further 
15 minutes. The cells were incubated with primary monoclonal antibodies for p50 (Abcam, 
UK) or p65 (Invitrogen, UK) for 1 hour then incubated with fluorescently-labelled 
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secondary antibodies (p65: Dylight 488 (Abcam, UK); p50: CFL-555 (Santa Cruz 
Biotechnology)) for 1 hour. Cells were counterstained with 150nM of DAPI (4′,6-
Diamidino-2-phenylindole dihydrochloride; Sigma Aldrich, UK) and visualized using 
Nikon Eclipse 80i (Nikon UK Ltd., Surrey, UK). Images were captured using Volocity 5.5 
(Perkin Elmer, UK). 
2.7. Statistical analysis 
All data are presented as mean ± standard deviation (SD). One-way or Two-way analysis 
of Variance (ANOVA) was conducted for within group comparisons. The statistical 
package, Graphpad Prism 7.0 was used for statistical analyses. Statistically significant 
differences between treatments are denoted as * for p <0.05; p <0.01 (**) or p< 
0.001(***). Error bars represent standard deviation of at least 3 replicates. 
3. Results 
3.1. V-2 down-regulates proinflammatory cytokines in THP-1 cells and primary 
mononuclear cells. 
We initially determined if pre-treatment of dTHP-1 cells with V-2 can regulate LPS-
induced inflammatory cytokine secretion. As shown in Fig 1A and 1B, V-2 pre-treatment 
over a concentration range of 16-160nM significantly down-regulated LPS-induced TNF-α 
and IL-1β secretion with no significant effect on cell-viability.  On the basis of the data in 
Figs. 1A and 1B, further studies on the modulatory actions of V-2 were restricted to using 
the 80nM concentration. Given that the assembly of NLRP3 inflammasome mediates the 
processing and release of both IL-1β and IL-18 [5, 16] we also explored the effect of V-2 
on the release of IL-18. Fig. 1C confirms that like IL-1β, a significant reduction in LPS-
induced IL-18 was observed following V-2 pre-treatment (LPS: 117.4 ± 9.3 vs V-2 + LPS: 
66.6 ± 6.3 pg/ml). We also explored if the inflammation modulatory ability of V-2 that we 
observed in dTHP-1 cells was also present in primary mononuclear cells. As was seen with 
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dTHP-1 cells, LPS-induced TNF-α and IL-1β secretion were significantly reduced by V-2 
pre-treatment (fig. 1D), supporting the view that the modulatory effects of V-2 was not 
unique to dTHP-1cells. 
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Figure 1. V-2 down-regulates proinflammatory cytokine secretion. (A, B) dTHP-1 
cells were pre-treated with a range of concentration of V-2 (1.6-160nM) for 1 hour then 
stimulated with 100 ng/ml LPS. The level of TNF-α and IL-1β was measured by ELISA in 
cell-free media at 6 and 24 hours, respectively. Treatment of cells with 1.6-160nM of V-2 
alone did not change cytokine expression (Data not shown). (C) dTHP-1 cells were pre-
treated with 80nM V-2 for 1 hour and then stimulated with 100ng/ml LPS for 24 hours and 
the level of IL-18 was determined in cell culture supernatants. (D) Effect of V-2 on 
primary mononuclear cells. Primary mononuclear cells were pre-treated with 80nM of V-2 
for 1 hour then stimulated with 100 ng/ml LPS. The level of TNF-α and IL-1β was 
measured in cell-free media by ELISA at 6 and 24 hours, respectively. Data represents 
mean ± S.D (n=3). 
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3.2. V-2 attenuates NF-κB reporter activity and phosphorylation of IKB-α.   
To elucidate the mechanism by which V-2 regulates inflammatory cytokine release, we 
hypothesized that the major regulator of inflammatory cytokine release, NF-κB [6], is 
affected by V-2 pre-treatment.  We investigated the ability of V-2 to regulate nuclear 
translocation of NF-κB p50 and p65 subunits using immunofluorescence. Fig. 2A 
demonstrates that V-2 pre-treatment alone induces enhanced nuclear translocation of the 
p50 subunit, while LPS treatment induced co-localization of both p50 and p65.  Pre-
treatment of cells with V-2 followed by LPS challenge resulted in reduced nuclear staining 
of p65 and enhanced p50. We would contend that these data is supportive of V-2 inducing 
enhanced anti-inflammatory activity through p50 homodimerization. To further explore 
whether V-2 is capable of selectively targeting NF-κB activity, mediated through the 
activation of p50/p65 heterodimers, we employed a reporter assay with a specific p50/p65 
construct as originally described by [17]. The transfection efficiency of dTHP cells with 
NF-κB was very low; therefore we used HEK293T cells to determine the role of V-2 in 
regulating NF-κB activity. As shown in Fig. 2B, pre-treatment of HEK293T cells with V-2 
significantly decreased TNF-α induced NF-κB activity (TNF-α: 32.7 ± 0.5-fold vs V-2 + 
TNF-α: 24.8 ± 1.5-fold). IKB-α regulates the nuclear translocation of the p50/p65 
heterodimers by sequestering the complex in the cytoplasm [18]. Upon stimulation of cells 
IKB-α is phosphorylated and degraded [6], allowing the nuclear translocation of the 
p50/p65 heterodimer and activation of NF-κB. Accordingly, we explored whether V-2 
could attenuate LPS induced phosphorylation of IKB-α in dTHP-1 cells. Fig. 2C 
demonstrates that V-2 pre-treatment markedly inhibited LPS-induced phosphorylation of 
IKB-α.   
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Figure 2. Effect of V-2 on NF-κB signalling. (A) Confocal microscopy analysis of the 
location of p50 and p65 subunits of NF-κB in dTHP-1 cells. Cells were pre-treated with V-
2 for 1 hour before stimulation with LPS for 30 minutes. Cells were fixed, permeabilized 
and immunolabelled with primary antibodies for p50 and p65. Secondary antibodies 
conjugated to Dylight 488 (green) and CFL 555 (red) was raised against p65 and p50 
antibodies, respectively. DAPI (blue) was used to counterstain cell nuclei. The scale bar 
represents 5 µm. (B) Effect of V-2 on NF-κB reporter activity. HEK-293T cells cultured to 
80% confluence then pre-treated with V-2 for 1 hour before stimulation with 10 ng/ml of 
TNF-. Cells were lysed after 24 hours and gene-reporter activity was determined using 
the Dual-glo luciferase assay. (C) Effect of V-2 on LPS-induced phosphorylation of IKB-
α. Differentiated THP-1 cells were pre-treated with or without V-2 for 1 hour and then 
stimulated with 100 ng/ml of LPS for 30 minutes. The protein expression of IKB-α and 
Phospo-IKBα was analysed by immunoblotting. Data represents mean ± S.D (n=3). 
A 
B C 
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3.2. V-2 down-regulates the expression of NLRP3 and increases the expression of the 
regulators of inflammation, IL-10 and IL-1 receptor antagonist and TET-2 in the 
presence of LPS 
After demonstrating the effect of V-2 on NF-κB signalling cascade, the effect of V-2 on 
the expression of anti-inflammatory cytokine (IL-10), NLRP3 inflammasome and its 
regulators (IL-1Ra and TET-2) was determined. IL-10 is produced by macrophages to 
down-regulate LPS-stimulated TNF-α expression [19].  Fig. 3A demonstrates that V-2 
treatment alone significantly up-regulated IL-10 expression at 6 and 24 hours (6.9 ± 0.2 
and 5.9 ± 0.9-fold, respectively).  The pattern of IL-10 expression with LPS treatment was 
similar to that of V-2 at both 6 and 24 hour time points, however, co-stimulation of dTHP-
1 cells with V-2 and LPS significantly increased IL-10 expression at 24 hours compared to 
V-2 or LPS treatments alone. We further explored whether the significant reductions in 
LPS-induced IL-1β and IL-18 secretion (Figs. 1B and 1C) were associated with changes in 
NLRP3 expression by qRT-PCR. Fig. 3B demonstrates that gene expression of NLRP3 was 
itself significantly down regulated by V-2 in dTHP-1 cells stimulated by LPS. 
IL-1Ra negatively regulates NLRP3 inflammasome activation [20], consequently, we 
hypothesized that V-2 can modulate IL-1Ra expression. Fig. 3C demonstrates that 
although V-2 treatment alone did not increase IL-1Ra expression, pre-treatment of cells 
with V-2 before LPS treatment significantly increased IL-1Ra expression at 6 hours (LPS: 
69.6 ± 0.5 vs V-2 + LPS: 76.8 ± 0.2) and 24 hours (LPS: 55.9 ± 0.3 vs V-2 + LPS: 62.8 ± 
0.2), respectively.  Given the interest in the role of TET-2 in the regulation of the NLRP3 
inflammasome [21], we also explored if V-2 was capable of modulating TET-2 expression 
both in the presence and absence of LPS. Fig. 3D demonstrates that V-2 treatment alone 
significantly increased TET-2 expression at 6 hours post-stimulation (V-2: 2.4 ± 0.1-fold 
increase). LPS treatment induced a significant increase in TET-2 expression and a further 
11 
 
increase was observed following pre-treatment with V-2 at 6 hours (LPS: 3.6 ± 0.2 vs V-2 
+ LPS: 4.0 ± 0.1) and 24 hours (LPS: 4.5 ± 0.1 vs V-2 + LPS: 5.6 ± 0.1), respectively. 
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Figure 3. Effect of V-2 and/or LPS on (A) IL-10, (B) NLRP3, (C) IL-1Ra and (D) TET-
2 mRNA expression. dTHP-1 cells were pre-treated with 80nM V-2 (or VC) for 1 hour 
before stimulation with 100 ng/ml LPS for 6 and 24 hours. Gene expression at the mRNA 
level of IL-10, NLRP3, IL-1Ra and TET-2 was determined by qRT-PCR. Data represents 
mean ± S.D (n=3). 
4. Discussion 
This study demonstrates that V-2 significantly down-regulates LPS induced inflammatory 
cytokine secretion in both dTHP-1 cells and in primary human mononuclear cells. We also 
present data showing that V-2 inhibits NF-κB reporter activity and increased 
homodimerization of the p50 subunits of the transcription factor at the expense of p50/p65 
heterodimerization. Homodimerization of p50 subunit is known to induce IL-10 synthesis 
[22], a cytokine that is itself a regulator of inflammatory cytokine secretion. We would 
therefore propose that the anti-inflammatory actions of V-2 are in-part mediated by its 
ability to enhance p50 homodimerization and consequent IL-10 expression. The actions of 
A B 
C D 
12 
 
V-2, in regulating IL-1β and IL-18 secretion and the expression of IL-1Ra and NLRP3, 
supports an inflammasome modulating activity in dTHP-1 cells by V-2. Recently, Fuster et 
al. [11] demonstrated that TET-2 deficient macrophages exhibited an increase in IL-1β 
secretion in an NLRP3-dependent manner. This suggests that TET-2 plays an important 
role as a ‘gate-keeper’ of inflammasome related activity in macrophages. Thus, a novel 
aspect of this study was demonstrating that V-2 was capable of increasing TET-2 
expression and that this may be associated with its anti-inflammatory/inflammasome-
regulatory actions.  It could be argued that an increase in IL-10, IL-1Ra and TET-2 by an 
inflammatory mediator such as LPS is at first sight counterintuitive. However, Zhang et al. 
[14] demonstrated that LPS induces activation of TET-2 and that this event is critical to the 
resolution of the inflammatory response in macrophages.  Jaiswal et al. [12] and Fuster et 
al. [11] linked the actions of TET-2 to clonal haematological malignancies and the CHIP 
mutation of TET-2. However, these studies confirmed a role for TET-2 in regulating the 
inflammasome, both in the presence and absence of the CHIP mutation. THP-1 cells are of 
human myelomonocytic lineage, but to best of our knowledge the CHIP mutation has not 
been reported in THP-1 cells. 
In conclusion, we propose that V-2 has anti-inflammatory actions that are associated not 
only with increased IL-10 and IL-1Ra expression but also with increased TET-2 
expression. We further propose that V-2’s actions are mediated through its ability to 
regulate NF-κB activity and enhance homodimerization of the p50 subunit. Figure 4 
presents a proposed mechanistic model of the actions of V-2 as it relates to NF-κB and 
NLRP3 inflammasome signalling in macrophages. It remains to be seen if these anti-
inflammatory actions of V-2 can be definitively linked to TET-2 activity and that these 
actions are mirrored in a range of other relevant cell types. 
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Fig 4. Mechanistic model of NF-κB/NLRP3 inflammasome-modulatory actions of 
Vicenin-2 (V-2) in human macrophages.  NF-κB: NF-κB response element; TET-2: Ten-
eleven translocation-2.  
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